BREMSO: a simple score to predict early the natural course of multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10295799" target="_blank" >RIV/00216208:11110/15:10295799 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10295799

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ene.12696" target="_blank" >http://dx.doi.org/10.1111/ene.12696</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ene.12696" target="_blank" >10.1111/ene.12696</a>

Jazyk výsledku

angličtina

Název v původním jazyce

BREMSO: a simple score to predict early the natural course of multiple sclerosis

Popis výsledku v původním jazyce

Background and purposeEarly prediction of long-term disease evolution is a major challenge in the management of multiple sclerosis (MS). Our aim was to predict the natural course of MS using the Bayesian Risk Estimate for MS at Onset (BREMSO), which gives an individual risk score calculated from demographic and clinical variables collected at disease onset. MethodsAn observational study was carried out collecting data from MS patients included in MSBase, an international registry. Disease impact was studied using the Multiple Sclerosis Severity Score (MSSS) and time to secondary progression (SP). To evaluate the natural history of the disease, patients were analysed only if they did not receive immune therapies or only up to the time of starting thesetherapies. ResultsData from 14211 patients were analysed. The median BREMSO score was significantly higher in the subgroups of patients whose disease had a major clinical impact (MSSS third quartile vs. first quartile, P<0.00001) and who

Název v anglickém jazyce

BREMSO: a simple score to predict early the natural course of multiple sclerosis

Popis výsledku anglicky

Background and purposeEarly prediction of long-term disease evolution is a major challenge in the management of multiple sclerosis (MS). Our aim was to predict the natural course of MS using the Bayesian Risk Estimate for MS at Onset (BREMSO), which gives an individual risk score calculated from demographic and clinical variables collected at disease onset. MethodsAn observational study was carried out collecting data from MS patients included in MSBase, an international registry. Disease impact was studied using the Multiple Sclerosis Severity Score (MSSS) and time to secondary progression (SP). To evaluate the natural history of the disease, patients were analysed only if they did not receive immune therapies or only up to the time of starting thesetherapies. ResultsData from 14211 patients were analysed. The median BREMSO score was significantly higher in the subgroups of patients whose disease had a major clinical impact (MSSS third quartile vs. first quartile, P<0.00001) and who

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Neurology

ISSN

1351-5101

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

981-989

Kód UT WoS článku

000353994900018

EID výsledku v databázi Scopus

2-s2.0-84928369183